Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease

Keyphrases

• High Risk 100%
• Cyclophosphamide 100%
• Methotrexate 100%
• Etoposide 100%
• Gestational Trophoblastic Disease 100%
• Actinomycin D 100%
• Complete Response 50%
• Placental Site Trophoblastic Tumor 50%
• Treatment Cycle 50%
• Chemotherapy 25%
• Overall Survival 25%
• Life-threatening 25%
• Thrombocytopenia 25%
• Peripheral Neuropathy 25%
• Highly Effective 25%
• National Cancer Institute 25%
• Nausea 25%
• Fever 25%
• Disease-free 25%
• Diarrhea 25%
• 2-cycles 25%
• Neutropenia 25%
• Cisplatin-based Chemotherapy 25%
• Treatment Delay 25%
• Vomiting 25%
• Partial Response 25%
• Alopecia 25%
• Conjunctivitis 25%
• World Health Organization Criteria 25%
• Stomatitis 25%
• Serum hCG 25%
• Anemia Requiring Transfusion 25%
• Gestational Choriocarcinoma 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Dactinomycin 100%
• Etoposide 100%
• Cyclophosphamide 100%
• Methotrexate 100%
• Trophoblastic Tumor 100%
• Trophoblastic Disease 100%
• Vincristine 100%
• Chemotherapy 40%
• Cisplatin 20%
• Malignant Neoplasm 20%
• Overall Survival 20%
• Diarrhea 20%
• Neuropathy 20%
• Nausea and Vomiting 20%
• Alopecia 20%
• Stomatitis 20%
• Anemia 20%
• Thrombocytopenia 20%
• Neutropenia 20%
• Choriocarcinoma 20%
• Diseases 20%